abstract |
The present invention relates to novel fused pyrimidine derivative compounds. The compounds of the present invention can effectively inhibit exon 19 deletion, L858R mutation, exon 20 insertion, and T790M mutant epithelial cell growth factor receptor kinase. Therefore, the novel fused pyrimidine derivatives according to the present invention can be used for the treatment of cancer caused by activation of the mutant epithelial cell growth factor receptor kinase. |